Neurological soft signs in non-psychotic patients with cannabis dependence

Addiction Biology

Volumn 18, Issue 2, 2013, Pages 214-221

  Dervaux, Alain ^a,b   Bourdel, Marie Chantal ^b   Laqueille, Xavier ^a   Krebs, Marie Odile ^b,c  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cannabis; cerebellum; motor coordination; psychosis; sensory integration; substance abuse

Indexed keywords

ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC INTERVIEW FOR GENETIC STUDIES; DSM-IV; EDUCATION; FEMALE; HUMAN; MALE; MOTOR COORDINATION; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROLOGICAL SOFT SIGN; OUTPATIENT; PRIORITY JOURNAL; RANK SUM TEST; SENSORIMOTOR INTEGRATION; STANDARDIZED NEUROLOGICAL EXAMINATION FOR NEUROLOGICAL SOFT SIGNS; STRUCTURED INTERVIEW;

ADOLESCENT; ADULT; AGE OF ONSET; ANALYSIS OF VARIANCE; CANNABINOID RECEPTOR AGONISTS; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM DISEASES; CEREBELLUM; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MARIJUANA ABUSE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PARIS; PSYCHOMOTOR PERFORMANCE; RECEPTORS, CANNABINOID; SCHIZOPHRENIA; SUBSTANCE ABUSE TREATMENT CENTERS; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 84874411574     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2010.00261.x     Document Type: Article

References (58)

1. Andreasen NC, Pierson R, (2008) The role of the cerebellum in schizophrenia. Biol Psychiatry 64: 81-88.
2. Arango C, Bartko JJ, Gold JM, Buchanan RW, (1999) Prediction of neuropsychological performance by neurological signs in schizophrenia. Am J Psychiatry 156: 1349-1357. (Pubitemid 29416530)
3. Barnes TRE, (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676. (Pubitemid 19154942)
4. Barrigõn ML, Gurpegui M, Ruiz-Veguilla M, Diaz FJ, Anguita M, Sarramea F, Cervilla J, (2010) Temporal relationship of first-episode non-affective psychosis with cannabis use: a clinical verification of an epidemiological hypothesis. J Psychiatr Res 44: 413-420.
5. Bender S, Weisbrod M, Resch F, (2007) Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia? J Neural Transm 114: 1199-1215. (Pubitemid 47313173)
6. Berney A, Preisig M, Matthey ML, Ferrero F, Fenton BT, (2002) Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of alcohol and drug diagnoses. Drug Alcohol Depend 65: 149-158. (Pubitemid 34084898)
7. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK, (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764-774.
8. Block RI, O'Leary DS, Hichwa RD, Augustinack JC, Ponto LL, Ghoneim MM, Arndt S, Ehrhardt JC, Hurtig RR, Watkins GL, Hall JA, Nathan PE, Andreasen NC, (2000) Cerebellar hypoactivity in frequent marijuana users. Neuroreport 11: 749-753. (Pubitemid 30173917)
9. Bombin I, Arango C, Buchanan RW, (2005) Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull 31: 962-977. (Pubitemid 41437791)
10. Bottmer C, Bachmann S, Pantel J, Essig M, Amann M, Schad LR, Magnotta V, Schröder J, (2005) Reduced cerebellar volume and neurological soft signs in first-episode schizophrenia. Psychiatry Res 140: 239-250. (Pubitemid 41660968)
11. Budney AJ, Hughes JR, Moore BA, Vandrey R, (2004) Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161: 1967-1977. (Pubitemid 39441395)
12. Cavanagh JB, Holton JL, Nolan CC, (1997) Selective damage to the cerebellar vermis in chronic alcoholism: a contribution from neurotoxicology to an old problem of selective vulnerability. Neuropathol Appl Neurobiol 23: 355-363. (Pubitemid 27440475)
13. Chan RC, Xu T, Heinrichs RW, Yu Y, Gong QY, (2010) Neurological soft signs in non-psychotic first-degree relatives of patients with schizophrenia: a systematic review and meta-analysis. Neurosci Biobehav Rev 34: 889-896.
14. Chan RC, Xu T, Heinrichs RW, Yu Y, Wang Y, (2009) Neurological soft signs in schizophrenia: a meta-analysis. Schizophr Bull in press. Published online by Oxford University Press, 24 July 2009: doi:10.1093/schbul/sbp073
15. Chang L, Yakupov R, Cloak C, Ernst T, (2006) Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 129: 1096-1112.
16. Cooper ZD, Haney M, (2008) Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol 3: 188-195. (Pubitemid 351698888)
17. Dazzan P, Morgan KD, Chitnis X, Suckling J, Morgan C, Fearon P, McGuire PK, Jones PB, Leff J, Murray RM, (2006) The structural brain correlates of neurological soft signs in healthy individuals. Cereb Cortex 16: 1225-1231. (Pubitemid 44025391)
18. Dazzan P, Morgan KD, Orr KG, Hutchinson G, Chitnis X, Suckling J, Fearon P, Salvo J, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM, (2004) The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain 127: 143-153. (Pubitemid 38055353)
19. Dazzan P, Murray RM, (2002) Neurological soft signs in first-episode psychosis: a systematic review. Br J Psychiatry 43: s50-s57. (Pubitemid 34983513)
20. Edwards CR, Skosnik PD, (2007) Cerebellar-dependent learning as a neurobehavioral index of the cannabinoid system. Crit Rev Neurobiol 19: 29-57.
21. Giles LL, DelBello MP, Gilbert DL, Stanford KE, Shear PK, Strakowski SM, (2008) Cerebellar ataxia in youths at risk for bipolar disorder. Bipolar Disord 10: 733-737.
22. Goldberger C, Dervaux A, Gourion D, Bourdel MC, Laqueille X, Lôo H, Krebs M-O, (2010) Variable individual sensitivity to cannabis among patients with schizophrenia. Int J Neuropsychopharmacol. Published online by Cambridge University Press, 9 June 2010: doi:10.1017/S1461145710000647
23. Gourion D, Goldberger C, Bourdel MC, Bayle FJ, Millet B, Olie JP, Krebs MO, (2003) Neurological soft-signs and minor physical anomalies in schizophrenia: differential transmission within families. Schizophr Res 63: 181-187. (Pubitemid 36929859)
24. Gourion D, Goldberger C, Olie JP, Lôo H, Krebs MO, (2004) Neurological and morphological anomalies and the genetic liability to schizophrenia: a composite phenotype. Schizophr Res 67: 23-31. (Pubitemid 38117088)
25. Guy W, (1976) Abnormal Involuntary Movement Scale (AIMS), In:, Guy W, ed. ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW Publication Number ADM 76-338), pp. 534-537. Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
26. Haney M, (2009) Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 14: 9-21.
27. Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF, (2008) Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 69: 1354-1363.
28. Henquet C, Murray R, Linszen D, van Os J, (2005) The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31: 608-612. (Pubitemid 41253312)
29. Ho BC, Mola C, Andreasen NC, (2004) Cerebellar dysfunction in neuroleptic naive schizophrenia patients: clinical, cognitive, and neuroanatomic correlates of cerebellar neurologic signs. Biol Psychiatry 55: 1146-1153. (Pubitemid 38739448)
30. Iversen L, (2003) Cannabis and the brain. Brain 126: 1252-1270. (Pubitemid 36644373)
31. Jones SH, Thornicroft G, Coffey M, Dunn G, (1995) A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 166: 654-659.
32. Krebs MO, Gut-Fayand A, Bourdel MC, Dischamp J, Olié JP, (2000) Validation and factorial structure of a standardized examination assessing neurological soft signs in schizophrenia. Schizophr Res 45: 245-260.
33. Krebs MO, Mouchet S, (2007) Neurological soft signs and schizophrenia: a review of current knowledge. Rev Neurol 163: 1157-1168.
34. Krebs MO, Pouget Y, Amado I, Gourion D, Goldberger C, Olié JP, Bourdel MC, (2003) Clinical correlates of neurological soft signs in schizophrenia: a multiple regression analysis. Schizophrenia Res 60 (Suppl. 1): 83.
35. Leweke FM, Koethe D, (2008) Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 13: 264-275. (Pubitemid 351692982)
36. Mechri A, Gassab L, Slama H, Gaha L, Saoud M, Krebs MO, (2010) Neurological soft signs and schizotypal dimensions in unaffected siblings of patients with schizophrenia. Psychiatry Res 175: 22-26.
37. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G, (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319-328. (Pubitemid 47094993)
38. Mouchet-Mages S, Canceil O, Willard D, Krebs MO, Cachia A, Martinot JL, Rodrigo S, Oppenheim C, Meder JF, (2007) Sensory dysfunction is correlated to cerebellar volume reduction in early schizophrenia. Schizophr Res 91: 266-269. (Pubitemid 46389356)
39. Niethammer R, Weisbrod M, Schiesser S, Grothe J, Maier S, Peter U, Kaufmann C, Schröder J, Sauer H, (2000) Genetic influence on laterality in schizophrenia? A twin study of neurological soft signs. Am J Psychiatry 157: 272-274. (Pubitemid 30080911)
40. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T, (1994) Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849-859. (Pubitemid 24985906)
41. O'Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, Watkins GL, Hichwa RD, Andreasen NC, (2003) Marijuana alters the human cerebellar clock. Neuroreport 14: 1145-1151. (Pubitemid 36930263)
42. Picard H, Amado I, Mouchet-Mages S, Olié JP, Krebs MO, (2008) The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences. Schizophr Bull 34: 155-172. (Pubitemid 350262281)
43. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D, (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58: 909-915. (Pubitemid 32937912)
44. Prasad KM, Sanders R, Sweeney J, Montrose D, Diwadkar V, Dworakowski D, Miewald J, Keshavan M, (2009) Neurological abnormalities among offspring of persons with schizophrenia: relation to premorbid psychopathology. Schizophr Res 108: 163-169.
45. Quickfall J, Crockford D, (2006) Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci 18: 18-32.
46. Rahn EJ, Hohmann AG, (2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 6: 713-737.
47. Rog DJ, (2010) Cannabis-based medicines in multiple sclerosis-a review of clinical studies. Immunobiology 215: 658-672.
48. Ruiz-Veguilla M, Gurpegui M, Barrigõn ML, Ferrín M, Marín E, Rubio JL, Gutiérrez B, Pintor A, Cervilla J, (2009) Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use. Schizophr Res 107: 158-164.
49. Schneider M, (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13: 253-263. (Pubitemid 351692985)
50. Simpson GN, Angus JWS, (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (Suppl. 44): 11-19.
51. Skosnik PD, Edwards CR, O'Donnell BF, Steffen A, Steinmetz JE, Hetrick WP, (2008) Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning. Neuropsychopharmacology 33: 1432-1440. (Pubitemid 351521714)
52. Sneider JT, Pope HG Jr, Silveri MM, Simpson NS, Gruber SA, Yurgelun-Todd DA, (2006) Altered regional blood volume in chronic cannabis smokers. Exp Clin Psychopharmacol 14: 422-428. (Pubitemid 44789963)
53. Stinson FS, Ruan WJ, Pickering R, Grant BF, (2006) Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 36: 1447-1460. (Pubitemid 44355980)
54. Thomann PA, Wüstenberg T, Santos VD, Bachmann S, Essig M, Schröder J, (2009) Neurological soft signs and brain morphology in first-episode schizophrenia. Psychol Med 39: 371-379.
55. Villares J, (2007) Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 145: 323-334. (Pubitemid 46237689)
56. Volkow ND, Mullani N, Gould L, Adler SS, Guynn RW, Overall JE, Dewey S, (1988) Effects of acute alcohol intoxication on cerebral blood flow measured with PET. Psychiatry Res 24: 201-209.
57. Weaver T, Madden P, Charles V, Stimson G, Renton A, Tyrer P, Barnes T, Bench C, Middleton H, Wright N, Paterson S, Shanahan W, Seivewright N, Ford C, (2003) Comorbidity of substance misuse and mental illness collaborative study team. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry 183: 304-313. (Pubitemid 37243901)
58. Wong DF, Maini A, Rousset OG, Brasic JR, (2003) Positron emission tomography-a tool for identifying the effects of alcohol dependence on the brain. Alcohol Res Health 27: 161-173. (Pubitemid 39406798)